Wegovy (Semaglutide) Injection Pen for Weight Loss
Wegovy is a prescription-only weight loss treatment available following a comprehensive online clinical assessment. If clinically appropriate, your treatment will be prescribed by one of our qualified UK prescribers.
• Comprehensive online clinical assessment
• Reviewed by a qualified UK prescriber
• Ongoing clinical support throughout treatment
• Prompt, discreet UK delivery
Clinical Information
Wegovy contains semaglutide, a licensed GLP-1 receptor agonist designed to mimic natural metabolic hormones. In line with UK and NHS prescribing frameworks, Wegovy works by increasing feelings of fullness and delaying gastric emptying, supporting long-term weight reduction when combined with a calorie-controlled diet and increased physical activity.
Semaglutide (Weekly Injection)
BMI ≥30, or ≥27 with a weight-related medical condition.
Dispatched in secure, temperature-controlled packaging.
Dosing & Administration Guide
Wegovy must be administered exactly as prescribed by your medical professional. It follows a strict monthly escalation schedule to allow your body to adjust to the medication:
- Frequency: Inject your dose exactly once per week, on the same day each week. It can be taken at any time of day, with or without meals.
- Injection Sites: Administer subcutaneously (just under the skin) into the front of your thighs, the front of your abdomen, or your upper arms. Rotate your injection site each week.
- Dose Escalation: You will start on a low dose (0.25mg) for the first 4 weeks. Under clinical supervision, your weekly dose will gradually increase every 4 weeks through 0.5mg, 1.0mg, and 1.7mg, up to the maintenance dose of 2.4mg.
- Pen Storage: Unopened pens must be kept in a refrigerator (2°C to 8°C). Never freeze them. Once in use, the pen can be kept at room temperature (below 30°C) or in the fridge for up to 6 weeks.
Important Clinical Safety Details
Before initiating Wegovy, you must read the statutory patient safety warnings and verify your medical suitability during our clinical assessment.
- Common Side Effects: Nausea, vomiting, diarrhoea, constipation, and mild abdominal discomfort are common during the initial titration phase. These usually subside as your body adjusts. Stay hydrated if you experience gastrointestinal symptoms.
- Serious Risks: Discontinue treatment immediately and seek urgent medical attention if you experience severe, persistent abdominal pain radiating to your back, as this may indicate acute pancreatitis.
- Exclusions: Wegovy is strictly contraindicated if you or anyone in your family has ever had Medullary Thyroid Carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It cannot be used alongside any other GLP-1 medications or during pregnancy/breastfeeding.